Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2022 16:13 ET | Source: TYME Technologies, Inc.

Syros and Tyme Technologies Announce Stockholder Approval of Merger

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE...
September 07, 2022 08:00 ET | Source: TYME Technologies, Inc.

TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme

BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co....
May 25, 2022 07:15 ET | Source: TYME Technologies, Inc.

TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results

BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies...
March 29, 2022 06:50 ET | Source: TYME Technologies, Inc.

TYME Technologies, Inc. Announces Exploration of Strategic Options

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies...
March 09, 2022 06:50 ET | Source: Tyme Technologies, Inc.

TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022

-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation...
February 05, 2020 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Third Quarter Fiscal 2020 Financial and Operating Results

Strategic collaboration with Eagle Pharmaceuticals entitles TYME to receive up to a total of $40 million, which included $20 million upfront already received and $20 million in potential milestone...
January 27, 2020 08:00 ET | Source: Tyme Technologies, Inc.

Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care

The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer between 2009 to 2016, there was a reduction in non-medicine spending of $8 to $9 This preliminary...
January 16, 2020 08:00 ET | Source: Tyme Technologies, Inc.

TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneOral SM-88 represents a new approach designed to selectively disrupt protein synthesis...
January 08, 2020 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer

Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers - demonstrated responses in 15 different cancer types across four separate studiesData presented at...
December 04, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...